Fractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023. In the quarter to June 2026, revenue fell 57.1%, EPS grew 71.9%, free cash flow grew 25.3% and total debt rose 1.54%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow GUTS
Fractyl Health, Inc. (GUTS) Piotroski F-score
Fractyl Health, Inc.'s Piotroski F-score for fiscal 2024 cannot be worked out: needs three fiscal years.
Piotroski F-score, annual
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|
How fiscal 2024’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (74.55%) | — | Fail | 0 |
| Positive operating cash flow | (65.52m) | (42.82m) | Fail | 0 |
| Rising return on assets | (74.55%) | — | n/a | — |
| Cash flow above net income | 3.17m | 51.45m | Pass | 1 |
| Falling long-term leverage | 0.33 | — | n/a | — |
| Rising current ratio | 3.63 | 3.19 | Pass | 1 |
| No new shares issued | 43,542,000 | 2,081,000 | Fail | 0 |
| Rising gross margin | 46.24% | 35.83% | Pass | 1 |
| Rising asset turnover | 0.00 | — | n/a | — |
| Piotroski F-score | n/a — needs three fiscal years | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| GUTS Fractyl Health, Inc. | — |
| BOLD Boundless Bio, Inc. compare | — |
| RNTX Rein Therapeutics Inc. compare | — |
| GOSS Gossamer Bio, Inc. compare | — |
| ELOX Senesco Technologies Inc. compare | — |
| ALPS Alps Group Inc. compare | — |
| TENX Tenax Therapeutics, Inc. compare | — |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | — |
| RNXT RenovoRx, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover